{"id":"W2038906686","doi":"10.1002/ajh.23408","title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","year":2013,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Dasatinib; Myeloid leukemia; Rash; Phases of clinical research; Imatinib; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001176871,0.001251639,0.0016351,0.0003259643,0.0002892143,0.0005879609,0.0005266583,0.0008685076,0.002002772],"category_scores_gemma":[0.0006717863,0.0003976429,0.0008272668,0.0002389587,0.0005192853,0.0005749311,0.0002650177,0.001791315,0.0004538266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000501669,"about_ca_system_score_gemma":0.001034108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006156274,"about_ca_topic_score_gemma":0.001176244,"domain_scores_codex":[0.9996877,0.0001380865,0.00001754452,0.00004861403,0.00003151349,0.00007671803],"domain_scores_gemma":[0.9994953,0.00008641021,0.00009948761,0.00004697217,0.00003403089,0.0002377454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5408407,0.1568867,0.01203829,0.0006821837,0.0008045536,0.0008301039,0.0005150007,0.003676797,0.1545525,0.0004654232,0.00348781,0.1252198],"study_design_scores_gemma":[0.3642831,0.6122928,0.01241109,0.0000204561,0.0001507334,0.0005546114,0.00006390244,0.001890065,0.006483038,0.0001273629,0.001699454,0.00002336205],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971464,0.0003765926,0.0003311308,0.000174331,0.00004807659,0.001215978,0.0002343543,0.00003120873,0.0004419578],"genre_scores_gemma":[0.9941075,0.0004954549,0.001110941,0.0003839504,0.0001255916,0.001757778,0.0009746182,0.00001187575,0.001032236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002002772,"threshold_uncertainty_score":0.006699979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01233807531413088,"score_gpt":0.3062197094384318,"score_spread":0.2938816341243009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}